Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Hanx Biopharmaceuticals has dosed the first subject in a trial of HX044, a bispecific antibody designed for advanced solid tumours.

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of CC-42344 ...

According to GlobalData, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.

IMCA at the Israel Ministry of Health has renewed SciSparc’s trial of SCI-210 for treating paediatric patients with autism spectrum disorder.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in post-surgery pain compared to placebo.

Novartis is preparing to present the trial findings to regulatory bodies in 2025. Credit: Novartis AG. Novartis has reported positive topline outcomes from the Phase III STEER trial of an ...

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...